Pharmaceuticals, Biotechnology and Life Sciences
Durable Responses Observed in Refractory Biliary Tract Cancer (BTC) and Gastroesophageal (GEA) Cancers Enrollment Continues for Zanidatamab Global Pivotal Trial…
Durable Responses Observed in Refractory Biliary Tract Cancer (BTC) and Gastroesophageal (GEA) Cancers Enrollment Continues for Zanidatamab Global Pivotal Trial…
Durable Responses Observed in Refractory Biliary Tract Cancer (BTC) and Gastroesophageal (GEA) Cancers Enrollment Continues for Zanidatamab Global Pivotal Trial…
Durable Responses Observed in Refractory Biliary Tract Cancer (BTC) and Gastroesophageal (GEA) Cancers Enrollment Continues for Zanidatamab Global Pivotal Trial…
Durable Responses Observed in Refractory Biliary Tract Cancer (BTC) and Gastroesophageal (GEA) Cancers Enrollment Continues for Zanidatamab Global Pivotal Trial…
– 41% objective response rate (ORR) observed to-date across first four cohorts in the Phase 1 dose-escalation portion of ARC-8,…
LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced interim results from the biliary tract cancers cohort of…
– 41% objective response rate (ORR) observed to-date across first four cohorts in the Phase 1 dose-escalation portion of ARC-8,…
LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced interim results from the biliary tract cancers cohort of…
– 41% objective response rate (ORR) observed to-date across first four cohorts in the Phase 1 dose-escalation portion of ARC-8,…